Fractyl Health, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
GUTS Nasdaq 3840 fractyl.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fractyl Health, Inc.

Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort - Jan 13th, 2025 12:00 pm
Here’s Why Fractyl Health, Inc. (NASDAQ:GUTS) Is Among the Best Diabetes Stocks to Buy Under $10 - Jan 6th, 2025 2:10 pm
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) - Dec 12th, 2024 12:00 pm
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) - Dec 9th, 2024 12:00 pm
Fractyl Health to Participate in the Upcoming December Conferences - Nov 26th, 2024 12:00 pm
Fractyl Health Third Quarter 2024 Earnings: US$0.48 loss per share (vs US$9.61 loss in 3Q 2023) - Nov 14th, 2024 12:08 pm
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates - Nov 12th, 2024 9:05 pm
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024 - Nov 4th, 2024 9:05 pm
Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024 - Nov 4th, 2024 12:00 pm
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 - Oct 29th, 2024 11:00 am
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024 - Oct 28th, 2024 11:00 am
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference - Sep 24th, 2024 11:00 am
Fractyl Health to Participate in Upcoming September Investor Conferences - Sep 3rd, 2024 11:00 am
Fractyl Health Second Quarter 2024 Earnings: US$0.36 loss per share (vs US$14.56 loss in 2Q 2023) - Aug 16th, 2024 12:35 pm
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates - Aug 14th, 2024 8:05 pm
Rising diabetes rates spur growth in weight management solutions - Aug 12th, 2024 2:53 pm
Fractyl Health touts positive year-long weight loss results for Revita device - Aug 8th, 2024 4:13 pm
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure - Aug 8th, 2024 12:00 pm
Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 - Aug 7th, 2024 11:00 am
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs - Jul 30th, 2024 11:00 am